Features of Intracellular Matrix State during Development and Formation of COPD Clinical Phenotypes
https://doi.org/10.58838/2075-1230-2024-102-4-84-92
Abstract
The objective: to evaluate state of extracellular matrix markers and their tissue inhibitors during development and formation of clinical phenotypes of COPD, in patients facing the high risk of developing exacerbations.
Subjects and Methods. 96 COPD patients (73% men and 27% women) were examined. Patients were randomized into the following groups: Group 1 included 40 COPD patients with bronchitis phenotype; Group 2 included 38 patients with emphysema phenotype; and Control Group consisted of 18 practically healthy subjects. All patients underwent a comprehensive clinical and laboratory examination. Levels of matrix metalloproteinases (total MMP-9 and MMP-2) and their tissue inhibitors TIMMP1 and TIMMP2 were determined by ELISA.
Results. The development of COPD, regardless of the clinical phenotype of the disease, is accompanied by pronounced expression of extracellular matrix markers MMP-9 and MMP-2. Regardless of the COPD clinical phenotype, elevated activity of metalloproteinases is accompanied by inhibition of production of TIMMP2 and dysfunction of the MMP-9/TIMMP1 antiprotease system. In COPD patients with MMP-2 level of 214 ng/ml, the formation of bronchitis phenotype can be predicted, while with MMP-2 level of 214 ng/ml or more, the formation of emphysema phenotype can be predicted.
About the Authors
T. V. Tayutina
Rostov State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Tatiana V. Tayutina, Candidate of Medical Sciences, Associate Professor, Head of Polyclinic and Emergency Therapy Department
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: +7 (863) 250-41-16
S. V. Shlyk
Rostov State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Sergey V. Shlyk, Doctor of Medical Sciences, Provost, Professor, Head of Department of Medical Law, Public Health and Healthcare
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: +7 (863) 250-41-16
D. A. Kudlay
I.M. Sechenov First Moscow State Medical University (Sechenov University), Russian Ministry of Health; Lomonosov Moscow State University; Immunology Research Institute by Federal Medical Biological Agency
Russian Federation
Russian Federation
Dmitry A. Kudlay, Correspondent Member of RAS, Doctor of Medical Sciences, Professor of Pharmacology Department of Pharmacy Institute, Leading Researcher of Laboratory of Personalized Medicine and Molecular Immunology no. 71., Professor of Department of Pharmacognosy and Industrial Pharmacy, Faculty of Fundamental Medicine
8 Bd. 2, Trubetskaya St., Moscow, 119991
Phone: +7 (499) 248-05-53
S. V. Smerdin
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Sergey V. Smerdin, Doctor of Medical Sciences, Professor, Head Physician, Head of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
L. A. Shovkun
Rostov State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Lyudmila A. Shovkun, Doctor of Medical Sciences, Professor, Head of Tuberculosis Department
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: +7 (863) 250-41-16
E. A. Kizhevatova
Rostov State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Elena A. Kizhevatova, Senior Lecturer at Department of Medical Physics, Mathematics and Information Technologies
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: +7 (863) 250-41-16
N. Yu. Nikolenko
Moscow Research and Clinical Center for Tuberculosis Control, Moscow Government Department of Health
Russian Federation
Russian Federation
Nikolay Yu. Nikolenko, Candidate of Pharmacological Sciences, Researcher of Research Clinical Department
10 Stromynka St., Moscow, 107014
Phone: + 7 (499) 268-00-05
E. D. Kampos
Rostov State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Elena D. Kampos, Candidate of Medical Sciences, Associate Professor of Tuberculosis Department
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: +7 (863) 250-41-16
References
1. Gnoevykh V.V., Gening T.P., Portnova Yu.A. et al. Matrix metalloproteinases and clinical and functional status in smokers with persistent asthma. Therapeutic Archive, 2014, vol. 86, no. 8, pp. 29-34. (In Russ.)
2. Grigorkevich O.S., Mokrov G.V., Kosova L.Yu. Matrix metalloproteinases and their inhibitors. Pharmacokinetics and Pharmacodynamics, 2019, no. 2, pp. 3-16. (In Russ.)
3. Klinicheskiye rekomendatsii – KHOBL - 2021-2022-2023 (23.06.2021). [Guidelines on COPD management - 2021-2022-2023 (23.06.2021)]. Approved by the Russian Ministry of Health. Available: https://spulmo.ru/ Accessed July 03, 2024
4. Markelova E.V., Zdor V.V., Romanchuk A.L., Birko O.N. Matrix metalloproteinases: relationship with cytokines system, diagnostic and prognostic potential. Immunopathology, Allergology, Infectology, 2016, no. 2, pp. 11-22. (In Russ.) https://doi.org/10.14427/jipai.2016.2.11
5. Mikheev A.V., Baskevich M.A. The role of matrix metalloproteinases in the development of lung diseases. Nauka Molodykh (Eruditio Juvenium), 2015, no. 1, pp. 106-115. (In Russ.)
6. Rosstat, 2021. (In Russ.) Available: https://www.garant.ru/products/ipo/prime/doc/70749840/ Accessed July 03, 2024
7. Savchenko A.A., Kudlay D.A., Kudryavtsev I.V., Kasparov E.V., Golovkin A.S., Prodeus A.P., Borisov A.G. Tekhnologiya immunometabolicheskoy terapii. Klinicheskaya immunologiya dlya prakticheskikh vrachey. [Technology of immunometabolic therapy. Clinical immunology for practitioners]. Krasnoyarsk, AS-KIT Publ., 2023.
8. Smertnost naseleniya ot KHOBL. Statisticheskiye materialy. [COPD mortality rate. Statistical materials]. FGBU TNIIOIZ Publ., Moscow, 2021. Available: https://urniif.ru/ Accessed September 01, 2023
9. Starshinova A.A., Vishnevsky B.I., Graschenkov A.S., Maslyanskiy A.L., Kudlay D.A., Trufanov G.E. Printsipy differentsialnoy diagnostiki tuberkuleza organov dykhaniya i drugikh zabolevaniy legkikh: uchebnoye posobiye. [Principles of differential diagnosis of respiratory tuberculosis and other lung diseases: textbook]. Krasnoyarsk, AS-KIT Publ., 2024.
10. Tayutina T.V., Shlyk S.V., Vodopyanov A.S., Kazaryan T.M. Using the method of artificial neural networks for integration into the decision support system as a tool for optimizing outpatient management of patients with chronic obstructive pulmonary disease. Medical Herald of the South of Russia. 2024, vol. 15, no. 1, pp. 126-140. (In Russ.) https://doi.org/10.21886/2219-8075-2024-15-1-126-140
11. Tsvetkova O.A., Voronkova O.O., Buyanova O.E., Dubinin A.O. Metalloproteinases as biomarkers of chronic obstructive pulmonary disease progression. Pulmonologiya, 2023, vol. 33, no. 1, pp. 36-43. (In Russ.) https://doi.org/10.18093/0869-0189-2022-2354
12. Chuchalin A.G., Avdeev S.N., Aysanov Z.R., Belevskiy A.S., Leschenko I.V., Ovcharenko S.I., Shmelev E.I. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonologiya, 2022, vol. 32, no. 3, pp. 356-392. (In Russ.)https://doi.org/10.18093/0869-0189-2022-32-3-356-392
13. Shadrina A.S., Plieva Ya.Z., Kushlinskiy D.N. et al. Classification, regulation of activity, and genetic polymorphism of matrix metalloproteinases in health and disease. Almanac of Clinical Medicine, 2017, vol. 45, no. 4, pp. 266-279. (In Russ.) https://doi.org/10.18786/2072-0505-2017-45-4-266-279
14. Esmedlyaeva D.S., Alekseeva N.P., Gavrilov P.V., Pavlova M.V., Dyakova M.E., Sokolovich E.G. The predictive function of rates of matrix metalloproteinases/inhibitors system when assessing reparative changes in the lung tissue in those with infiltrate pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 9, pp. 38-44. (In Russ.) https:// doi.org/10.21292/2075-1230-2018-96-9-38-44
15. Yudina N.Yu., Nazarkina I.M., Kudlay D.A. Oksidantno-antioksidantnaya sistema eritrotsitov pri khronicheskoy obstruktivnoy bolezni legkikh. V sbornike: GBUZ SO Samarskaya gorodskaya klinicheskaya poliklinika № 15 g.o. Samara: 70 let sozidaniya i razvitiya - k novym dostizheniyam Sbornik nauchnykh rabot nauchno-prakticheskoy konferentsii. [Oxidant-antioxidant system of erythrocytes in chronic obstructive pulmonary disease. In Abst. Book: Samara City Clinical Clinic no. 15: 70 years of Creation and Progress – to New Achievements]. T.A. Larina, I.M. Nazarkina, eds., 2018, pp. 532-534.
16. Gelinas C., Puntillo K.A., Levin P. et al. The Behavior Pain Assessment Tool for critically illadults: A validation study in 28 countries. Pain, 2017, no. 158, pp. 811-821.
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of chronic obstructive pulmonary disease: 2023 Report. Available: https://gold-copd.org/ Accessed June 10, 2024
18. Ito K., Barnes P.J. COPD as a disease of accelerated lung aging. Chest, 2009, vol. 135, no. 1, pp. 173-180. https://doi.org/10.1378/chest.08-1419
19. Li Y., Lu Y., Zhao Z. et al. Relationships of MMP-9 and TIMP-1\\proteins with chronic obstructive pulmonary disease risk: a systematic systematic review and meta-analysis. J. Res. Med. Sci., 2016, no. 21, pp. 12. https://doi.org/10.4103/1735-1995.178737
20. McGuinness A.J.A., Sapey E. Oxidative stress in COPD: sources, markers, and potential mechanisms. J. Clin. Med., 2017, vol. 6, no. 2, pp. 21. https://doi.org/10.3390/jcm6020021
21. Stankovic M., Nikolic A., Nagorni-Obradovic L. et al. Genegene interactions between glutathione S-transferase M1 and matrix metalloproteinases 1, 9, and 12 in chronic obstructive pulmonary disease in Serbians. COPD, 2017, vol. 14, no. 6, pp. 581-589. https://doi.org/10.1080/15412555.2017.1369022
22. Taylor S.L., Rogers G.B., Chen A.C. et al. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann. Am. Thorac. Soc., 2015, vol. 12, no. 5, pp. 701-707. https://doi.org/10.1513/AnnalsATS.201411-513OC
23. Wang Y., Xu J., Meng Y., et al. Role of inflammatory cells in airway in COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2018, no. 13, pp. 3341-3348. https://doi.org/10.2147/COPD.S176122
Review
For citations:
Tayutina T.V., Shlyk S.V., Kudlay D.A., Smerdin S.V., Shovkun L.A., Kizhevatova E.A., Nikolenko N.Yu., Kampos E.D. Features of Intracellular Matrix State during Development and Formation of COPD Clinical Phenotypes. Tuberculosis and Lung Diseases. 2024;102(4):84-92. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-4-84-92
Views:
186
Email this article 